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          As cases of COVID-19, the disease caused by the novel coron-
       avirus (SARS-CoV-2), continue to spread globally, public health
        experts have warned about the devastating impact this pandemic
     may have on society’s mos t vul nera ble [ 1]. Meanwhile, another
         public health crisis, the opioid epidemic, rages on throughout the
            United States [ ]. In other parts of the world, the use of opiates2,3
        and opioids has remained relatively stable; however, in Eastern
          Europe, Russia and Central Asia opiate use has increased [4]. In
           these regions, the prevalence of injection drug use is high, as is
           prevalence of HIV among people who inject drugs over 40% in–
        major Russian cities according to recent estimates [ ]. World-5
            wide nearly half a million people died as a result of drug misuse
           in 2015; 168,000 of those deaths were due to overdose [6]. Pe o-
           ple living with HIV (PLWH) face higher risk of opioid misuse than
         HIV-negative people, in part because PLWH are more likely to
        suffer chronic pain and receive opioid analgesic treatment for
  symptom relief [7,8].
        People who use drugs (PWUD) face unique vulnerabilities in
       the COVID-19 era, including elevated homelessness and fre-
         quent interaction with criminal justice systems [ ]. In the United9
      States alone, approximately four million people experiencing
          homelessness cycle in and out of a variety of high-risk settings,
        including street encampments, shelters, jails and prisons. Each of
       these contexts present significant challenges to limiting the
          spread of COVID-19. On the streets, for example, the very sup-
        plies needed to follow World Health Organization (WHO) rec-
       ommended hand hygiene guidelines [ ], including access to10
         clean water, soap and hand sanitizer, are scarce. Prison over-
       crowding, which was an international health concern prior
        COVID-19 [ ], has reached a crisis point. Limited COVID-1911
         testing in correctional settings, scarce PPE for inmates and staff
        and COVID-19 outbreaks in prisons across the world make
      incarcerated PWUD especially vulnerable for COVID-19 infec-
      tion and resulting negative health outcomes [12].
        For PWUD in community settings, disruptions in global sup-
       ply chains and implementation of physical distancing measures
         in response to the COVID-19 pandemic may limit access to
        drugs and harm reduction services. The popular press has
       documented limited availability of fentanyl and other synthetic
        opioids due to closings of chemical manufacturing plants in
       Wuhan, China [ ]. Rising nationalism evidenced by policies13
        banning pharmaceutical and PPE exports, such as those insti-
          tuted by the United States and India [ ], and border closings,14
        such as those implemented in South America [ ], may15
       decrease the availability of certain drugs, including synthetic
         opioids. Whether disruptions in the drug supply chain are real
         or imagined, the fear experienced by PWUD has an immeasur-
         able effect on their wellbeing. In addition, harm reduction pro-
     grammes, including naloxone distribution and syringe
       exchange, have become increasingly difficult to access under
    “ ”shelter in place restrictions [ ].16
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       Decriminalization of PWUD and access to harm reduction
        services for PWUD must also be prioritized during the
       COVID-19 pandemic. Scholars have called for police and
       courts to immediately suspend arresting and sentencing peo-
        ple for low-level crimes and misdemeanors [ ], which often19
       include possession of drugs. Over 70 countries worldwide
       have introduced syringe exchange programmes [ ] and nalox-20
           one has saved tens of thousands of lives in the United States
        alone [ ]; however, access to these harm reduction services21
        remains difficult in many countries. Anticipated scarcity of syr-
       inges and other injection equipment during the COVID-19
        pandemic may prompt PWUD to share syringes or experiment
          with new drugs or new drug use habits. To prevent outbreaks
         of HIV, HCV and other infectious diseases among PWUD, pol-
          icy makers in nations with high rates of opioid use, including
        Russia and other Eastern European and Central Asian coun-
         tries where new COVID-19 cases are beginning to surge [ ],22
      would be wise to consider implementing government-sup-
       ported programmes to purchase and allocate syringes. WHO-
     endorsed naloxone distribution and training programmes
       should be re-considered in contexts where harm reduction
   programmes are outlawed [ ].6
      Finally, because various physical distancing measures in
         response to COVID-19 are anticipated to remain in place for
       the foreseeable future, PWUD may have difficulty accessing
      healthcare services, including opioid substitution therapy, med-
      ication-assisted treatment and other substance use treatment
      services. Telemedicine has been successfully implemented dur-
         ing other global emergencies [ ] and presents a key opportu-23
        nity for helping PWUD stay connected to services while
      protecting themselves against COVID-19 infection. PWUD in
        greatest need will require sustained access to technology that
       allows them to leverage telemedicine to facilitate engagement
      with critical healthcare services, including continuous contact
       with counsellors and addiction medicine specialists. In Canada,
      opioid substitution therapy is prescribed and administered
        through daily dispensing at pharmacies or as a take-home
       medication [ ]. During the COVID-19 pandemic some gov-24
       ernments have recommended home delivery of HIV medica-
      tions [ ]; similar considerations for opioid substitution25
       therapy and medication-assisted treatment may be possible in
       certain contexts. Uninterrupted access to cellular and internet
          service will also be crucial to the success of these pro-
grammes.
       As highlighted here, PWUD are especially vulnerable to
       COVID-19 given their increased risk for homelessness, inter-
         actions with criminal justice systems and need to access in-
      person services for substance use treatment. International
      leaders should consider programmes and policies outlined
         here in order to avoid a more concentrated epidemic of
        COVID-19 among PWUD. Millions of lives across the globe
  depend on it.
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